NR1H4 and inflammatory bowel disease: To determine whether FXR agonism ameliorates inflammation through gut macrophages before tumor initiation, we first examined the FXR signaling, cytokine production, and macrophage marker expression in patients with IBD (transcriptome and metatranscriptome meta-analysis cohort, TaMMA cohort) (41).